Citations

Clear

2303 citation(s) found for "Yu, Edward".

InSaccharomyces cerevisiae, yKu and Subtelomeric Core X Sequences Repress Homologous Recombination Near Telomeres as Part of the Same Pathway
Marvin, Marcus E., Griffin, Craig David., Eyre, David E., Barton, David B. H., Louis, Edward J.

Mayo Clinic

Genetics | August 4, 2009 | Volume: 183 | Issue: 2 | Pages: 441-451

10.1534/genetics.109.106674 | PMID 19652177 Get It

AbstractUnlike in meiosis where recombination near telomeres is repressed, subtelomeric regions appear to recombine with each other frequently in vegetative cells with no detrimental consequences. To test whether or not such recombination is prevented in the core of chromosomes for maintenance of genome stability, we measured allelic homologous recombination (HR) along chromosome arms and between different ectopic locations. We found that there is an increase of recombination at telomeres in wild-type cells compared with sequences at proximal subtelomeric and interstitial regions of the genome. We also screened for mutations that result in an increase in HR between a telomeric sequence and a more internal sequence, which normally exhibit very low rates of HR. YKU80 was hit most frequently in our screen, and we show that the yKu heterodimer specifically represses HR in the vicinity of telomeres. This repression of HR is not explained solely by the role of yKu in maintaining telomere length, silencing, or tethering to the nuclear periphery. Analysis of mutant strains harboring deleted core X sequences revealed a role for this subtelomeric element in preventing telomeric recombination. Furthermore, core X bestowed this protection as part of the same pathway as yKu. Our findings implicate a role for both yKu and core X in stabilizing the genome against recombination events involving telomeric sequences.
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Kumar, Shaji , Stadtmauer, Edward A. , Harousseau, Jean Luc, Palumbo, Antonio, Bensinger, William, Comenzo, Raymond L. , Lentzsch, Suzanne , Munshi, Nikhil C. , Niesvizky, Rubén, Miguel, Jesús F. San , Bergsagel, Leif, Bladé, Joan , Tosi, Patrizia , Sonneveld, Pieter , Sezer, Orhan , Vesole, David H., Cavo, Michèle , Richardson, Paul G. , Durie, Brian G.M. , Rajkumar, S. Vincent , Bergsagel, P. Leif , Giralt, Sergio , Ludwig, Heinz , Lonial, Sagar , Anderson, Kenneth C. , Einsele, Hermann , Richardson, Paul Gerard Guy , Bergsagel, P. Leif , Rajkumar, S Vincent , San-Miguel, Jesus

Mayo Clinic

Blood | June 27, 2009 | Volume: 114 | Issue: 9 | Pages: 1729-1735

10.1182/blood-2009-04-205013 | PMID 19561323 Get It

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization.
Prospective Comparison of State-of-the-Art MR Enterography and CT Enterography in Small-Bowel Crohn's Disease
Siddiki, Hassan , Fidler, Jeff L. , Burton, Sharon S., Huprich, James E., Hough, David M., Johnson, C. Daniel, Bruining, David H. , Loftus, Edward V. , Sandborn, William J. , Pardi, Darrell S. , Mandrekar, Jayawant N. , Fidler, Jeff L. , Fletcher, Joel G. , Loftus, Edward V

Mayo Clinic

American Journal of Roentgenology | June 19, 2009 | Volume: 193 | Issue: 1 | Pages: 113-121

10.2214/ajr.08.2027 | PMID 19542402 Get It

Lymphocyte Function-Associated Antigen 1 Is a Receptor forPasteurella haemolyticaLeukotoxin in Bovine Leukocytes
Jeyaseelan, Samithamby , Hsuan, Shih‐Ling, Kannan, Mathur , Walcheck, Bruce , Wang, J. F., Lally, Edward T., Sieck, Gary C. , Maheswaran, S. K., Kehrli, Marcus Eugene , Sieck, Gary

Mayo Clinic

Infection and Immunity | May 1, 2009 | Volume: 68 | Issue: 1 | Pages: 72-79

10.1128/iai.68.1.72-79.2000 | PMID 10603370 Get It

ABSTRACTPasteurella (Mannheimia) haemolyticaleukotoxin (Lkt) causes cell type- and species-specific effects in ruminant leukocytes. Recent studies indicate thatP. haemolyticaLkt binds to bovine CD18, the common subunit of all β2 integrins. We designed experiments with the following objectives: to identify which member of the β2 integrins is a receptor for Lkt; to determine whether Lkt binding to the receptor is target cell (bovine leukocytes) specific; to define the relationships between Lkt binding to the receptor, calcium elevation, and cytolysis; and to determine whether a correlation exists between Lkt receptor expression and the magnitude of target cell cytolysis. We compared Lkt-induced cytolysis in neutrophils from control calves and from calves with bovine leukocyte adhesion deficiency (BLAD), because neutrophils from BLAD-homozygous calves exhibit reduced β2 integrin expression. The results demonstrate for the first time that Lkt binds to bovine CD11a and CD18 (lymphocyte function-associated antigen 1 [LFA-1]). The binding was abolished by anti-CD11a or anti-CD18 monoclonal antibody (MAb). Lkt-induced calcium elevation in bovine alveolar macrophages (BAMs) was inhibited by anti-CD11a or anti-CD18 MAb (65 to 94% and 37 to 98%, respectively, at 5 and 50 Lkt units per ml;P< 0.05). Lkt-induced cytolysis in neutrophils and BAMs was also inhibited by anti-CD11a or anti-CD18 MAb in a concentration-dependent manner. Lkt bound to porcine LFA-1 but did not induce calcium elevation or cytolysis. In neutrophils from BLAD calves, Lkt-induced cytolysis was decreased by 44% compared to that of neutrophils from control calves (P< 0.05). These results indicate that LFA-1 is a Lkt receptor, Lkt binding to LFA-1 is not target cell specific, Lkt binding to bovine LFA-1 correlates with calcium elevation and cytolysis, and bovine LFA-1 expression correlates with the magnitude of Lkt-induced target cell cytolysis.
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
Stadtmauer, Edward A. , Nademanee, Auayporn, Micallef, Ivana N. , Stiff, Patrick J. , Hosing, Chitra , Früehauf, Stefan, Horwitz, Mitchell E. , Cooper, Dennis , Bridger, Gary, Calandra, Gary, Investigators, for the 3102, DiPersio, John F. , Kaufman, Jonathan L. , Maziarz, Richard Thomas , Investigators, for the 3102

Mayo Clinic

Blood | April 10, 2009 | Volume: 113 | Issue: 23 | Pages: 5720-5726

10.1182/blood-2008-08-174946 | PMID 19363221 Get It

Abstract This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mobilizing hematopoietic stem cells in patients with multiple myeloma. Patients received G-CSF (10 μg/kg) subcutaneously daily for up to 8 days. Beginning on day 4 and continuing daily for up to 4 days, patients received either plerixafor (240 μg/kg) or placebo subcutaneously. Starting on day 5, patients began daily apheresis for up to 4 days or until more than or equal to 6 × 106 CD34+ cells/kg were collected. The primary endpoint was the percentage of patients who collected more than or equal to 6 × 106 CD34+ cells/kg in less than or equal to 2 aphereses. A total of 106 of 148 (71.6%) patients in the plerixafor group and 53 of 154 (34.4%) patients in the placebo group met the primary endpoint (P < .001). A total of 54% of plerixafor-treated patients reached target after one apheresis, whereas 56% of the placebo-treated patients required 4 aphereses to reach target. The most common adverse events related to plerixafor were gastrointestinal disorders and injection site reactions. Plerixafor and G-CSF were well tolerated, and significantly more patients collected the optimal CD34+ cell/kg target for transplantation earlier compared with G-CSF alone. This study is registered at www.clinicaltrials.gov as #NCT00103662.
Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-β
Rahimi, Rod A. , Andrianifahanana, Mahefatiana, Wilkes, Mark C. , Edens, Maryanne, Blenis, John , Leof, Edward B. , Kottom, Theodore J.

Mayo Clinic

Cancer Research | December 31, 2008 | Volume: 69 | Issue: 1 | Pages: 84-93

10.1158/0008-5472.can-08-2146 | PMID 19117990 Get It

Abstract Transforming growth factor-β (TGF-β) promotes a multitude of diverse biological processes, including growth arrest of epithelial cells and proliferation of fibroblasts. Although the TGF-β signaling pathways that promote inhibition of epithelial cell growth are well characterized, less is known about the mechanisms mediating the positive response to this growth factor. Given that TGF-β has been shown to promote fibrotic diseases and desmoplasia, identifying the fibroblast-specific TGF-β signaling pathways is critical. Here, we investigate the role of mammalian target of rapamycin (mTOR), a known effector of phosphatidylinositol 3-kinase (PI3K) and promoter of cell growth, in the fibroblast response to TGF-β. We show that TGF-β activates mTOR complex 1 (mTORC1) in fibroblasts but not epithelial cells via a PI3K-Akt-TSC2–dependent pathway. Rapamycin, the pharmacologic inhibitor of mTOR, prevents TGF-β–mediated anchorage-independent growth without affecting TGF-β transcriptional responses or extracellular matrix protein induction. In addition to mTORC1, we also examined the role of mTORC2 in TGF-β action. mTORC2 promotes TGF-β–induced morphologic transformation and is required for TGF-β–induced Akt S473 phosphorylation but not mTORC1 activation. Interestingly, both mTOR complexes are necessary for TGF-β–mediated growth in soft agar. These results define distinct and overlapping roles for mTORC1 and mTORC2 in the fibroblast response to TGF-β and suggest that inhibitors of mTOR signaling may be useful in treating fibrotic processes, such as desmoplasia. [Cancer Res 2009;69(1):84–93]
The Significance of Atypia and Histologic Malignancy in Pilocytic Astrocytoma of the Cerebellum: A Clinicopathologic and Flow Cytometric Study
Tomlinson, Francis H., Scheithauer, Bernd W., Hayostek, Cherie J., Parisi, Joseph E. , Meyer, Fredric B. , Shaw, Edward G. , Weiland, Timothy L., Katzmann, Jerry A., Jack, Clifford R. , Jack, Clifford R

Mayo Clinic

Journal of Child Neurology | December 24, 2008 | Volume: 9 | Issue: 3 | Pages: 301-310

10.1177/088307389400900317 | PMID 7930411 Get It

Biologically malignant pilocytic astrocytomas are rare. Precise morphologic criteria permitting their identification and clinically meaningful distinction from more ordinary pilocytic astrocytomas have not been developed. The histologic grading schemes applied to fibrillary astrocytomas—ones based on nuclear atypia, increased cellularity, mitotic activity, endothelial proliferation, and necrosis—are thought not to correlate with prognosis in pilocytic astrocytomas. Nonetheless, these features were systematically sought in 107 cerebellar pilocytic astrocytomas, four of which were histologically malignant. The clinical, morphologic, and flow cytometric features of these cases were studied. The incidence of histologic malignancy occurring spontaneously in otherwise typical pilocytic astrocytomas was 0.9%; that occurring after radiation was 1.8%. The four histologically malignant tumors occurred in two males and two females, ages 6 to 18 years. All showed increased mitotic activity (three to five mitoses per high-power microscopic field [250×]). Endothelial proliferation and necrosis were present in three and two cases each. DNA ploidy analysis showed the spontaneously occurring malignant-appearing tumors to be aneuploid, whereas both previously radiated tumors were tetraploid; 5% to 11% of cells were in S phase. The appearance of histologic malignancy in pilocytic astrocytoma is rare and less reliably correlated with prognosis than in patients with fibrillary astrocytomas. Essential features of such tumors include a high mitotic index and perhaps a high percentage of cells in S phase. (J Child Neurol 1994;9:301-310).
Topical Review Article: Medulloblastoma: I. Clinical, Diagnostic, and Therapeutic Overview
Tomlinson, Frank H., Scheithauer, Bernd W., Meyer, Fredric B. , Smithson, William A., Shaw, Edward G. , Miller, Gary M. , Groover, Robert V.

Mayo Clinic

Journal of Child Neurology | December 24, 2008 | Volume: 7 | Issue: 2 | Pages: 142-155

10.1177/088307389200700203 | PMID 1573231 Get It

Medulloblastoma, the most common embryonal tumor of the central nervous system, affects both children and adults. It poses a significant therapeutic challenge in that age-dependent differences exist, not only in their pathobiology, but in the efficacy of chemotherapy and radiotherapy. This is particularly the case in very young children, whose still developing nervous system exhibits a low tolerance to radiotherapy. We review the epidemiology, clinical presentation, radiologic features, and current therapeutic concepts relative to this unique neoplasm. Efforts are made to highlight clinical controversies. ( J Child Neurol 1992;7:142-155).
Nomenclature of Natural Orifice Translumenal Endoscopic Surgery (NOTES ™ ) and Laparoendoscopic Single-Site Surgery (LESS) Procedures in Urology
Box, Geoffrey N., Averch, Timothy D. , Cadeddu, Jeffrey A., Cherullo, Edward E., Clayman, Ralph V. , Desai, Mihir , Frank, Igor, Gettman, Matthew T., Gill, Inderbir S. , Gupta, Mantu , Haber, Georges‐Pascal, Kaouk, Jihad , Landman, Jaime, Lima, Esteavao, Ponsky, Lee , Rané, Abhay, Sawyer, Mark D. , Humphreys, Mitchell R. , Group, for the Urologic NOTES Working, Lima, Estêvão , Group, for the Urologic NOTES Working, Gill, Inderbir S

Mayo Clinic

Journal of Endourology | December 2, 2008 | Volume: 22 | Issue: 11 | Pages: 2575-2582

10.1089/end.2008.0471 | PMID 19046097 Get It